Shares of Oric Pharmaceuticals, Inc. (ORIC) have gained 22% over the past four weeks to close the last trading session at $13.4, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.23 indicates a potential upside of 58.4%.The mean estimate comprises 13 short-term price targets with a standard deviation of $3.9. While the lowest estimate of $15.00 indicates an 11.9% increase from ...

Bloomin' Brands (BLMN) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.12%. A quarter ago, it was expected that this owner of Outback Steakhouse and other casual dining spots would post a loss of $0.12 per share when it actually produced a loss of $0.03, delivering a surprise of +7 ...

Enact Holdings, Inc. (ACT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since ...

分组1 - UFP Technologies reported quarterly earnings of $2.44 per share, exceeding the Zacks Consensus Estimate of $2.26 per share, with a year-over-year comparison showing a slight decrease from $2.46 per share [1] - The company achieved an earnings surprise of +7.81% for the quarter, following a previous surprise of +7.66% when it reported earnings of $2.39 per share against an expectation of $2.22 per share [1][2] - UFP's revenues for the quarter were $148.92 million, which fell short of the Zacks Consensus Estimate by 1.08%, but showed an increase from $144.07 million in the same quarter last year [2] 分组2 - The stock has gained approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $2.55 on revenues of $156.63 million, and for the current fiscal year, it is $10.58 on revenues of $635.48 million [7] 分组3 - The Medical - Instruments industry, to which UFP belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - UFP currently holds a Zacks Rank of 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) shows significant upside potential with a mean price target of $33.78, indicating an 117.1% increase from its current trading price of $15.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $5.4, where the lowest estimate is $22.00 (41.4% increase) and the highest is $39.00 (150.6% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KALV's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 29.2%, with two estimates moving higher and no negative revisions [12] - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14]

Group 1 - Nomad Foods (NOMD) closed at $12.92, with a 6.8% gain over the past four weeks, and analysts set a mean price target of $16.83, indicating a 30.3% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $1.47, where the lowest estimate is $15.00 (16.1% increase) and the highest is $18.00 (39.3% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NOMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

分组1 - Hims & Hers Health, Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.11 per share a year ago, resulting in an earnings surprise of +227.10% [1] - The company posted revenues of $617.82 million for the quarter ended December 2025, which was 0.22% below the Zacks Consensus Estimate, compared to $481.14 million in the same quarter last year [2] - Hims & Hers Health shares have declined approximately 51.9% year-to-date, contrasting with the S&P 500's gain of 0.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $645.27 million, and for the current fiscal year, it is $0.55 on revenues of $2.73 billion [7] - The Medical Info Systems industry, to which Hims & Hers Health belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

Core Viewpoint - Insmed (INSM) shows potential for significant upside, with a mean price target of $215.1 indicating a 33.6% increase from the current price of $161 [1]. Price Targets - The average of 20 short-term price targets ranges from a low of $162.00 to a high of $241.00, with a standard deviation of $19.56, suggesting variability in analyst estimates [2]. - The lowest estimate indicates a 0.6% increase, while the highest suggests a 49.7% upside [2]. Analyst Consensus and Earnings Estimates - Analysts are optimistic about INSM's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 16.1% over the past month, with three estimates rising and one falling [12]. - INSM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set unbiased targets has been questioned [3][10]. - Analysts often set optimistic price targets due to business incentives, which can lead to inflated estimates [8].

Core Viewpoint - Hinge Health Inc. (HNGE) shows potential for significant upside, with a mean price target of $58.25 indicating a 39% increase from its current price of $41.92 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets, with a standard deviation of $6.92, indicating variability among analysts [2] - The lowest estimate is $48.00, suggesting a 14.5% increase, while the highest estimate is $72.00, indicating a potential surge of 71.8% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about HNGE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 63.2% over the past month, with four estimates increasing and no negative revisions [12] - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by business incentives, leading to potentially inflated estimates [8]

Core Insights - Workiva (WK) reported quarterly earnings of $0.78 per share, exceeding the Zacks Consensus Estimate of $0.68 per share, and showing significant growth from $0.33 per share a year ago, resulting in an earnings surprise of +15.56% [1] - The company achieved revenues of $238.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.67% and increasing from $199.89 million year-over-year [2] Financial Performance - Workiva has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong financial performance [2] - The company's shares have declined approximately 32.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.5% [3] Future Outlook - The future performance of Workiva's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - Current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $238.98 million, and for the current fiscal year, it is $2.14 on revenues of $1.02 billion [7] Industry Context - The Internet - Software industry, to which Workiva belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Workiva's stock performance [5]